Verrica Pharmaceuticals (VRCA) Competitors

$5.87 -0.40 (-6.38%)

Closing price 05/18/2026 04:00 PM Eastern

Extended Trading

$5.82 -0.05 (-0.94%)

As of 06:42 AM Eastern

VRCA vs. CTNM, PRTA, OCGN, UPB, and KMDA

Should you buy Verrica Pharmaceuticals stock or one of its competitors? MarketBeat compares Verrica Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Verrica Pharmaceuticals include Contineum Therapeutics (CTNM), Prothena (PRTA), Ocugen (OCGN), Upstream Bio (UPB), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry.

How does Verrica Pharmaceuticals compare to Contineum Therapeutics?

Contineum Therapeutics (NASDAQ:CTNM) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Verrica Pharmaceuticals has lower revenue, but higher earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	$50M	9.62	-$59.98M	-$1.95	N/A
Verrica Pharmaceuticals	$35.58M	2.83	-$17.89M	-$1.03	N/A

Contineum Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -47.97%. Contineum Therapeutics' return on equity of -27.09% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-27.09%	-25.64%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

In the previous week, Verrica Pharmaceuticals had 4 more articles in the media than Contineum Therapeutics. MarketBeat recorded 7 mentions for Verrica Pharmaceuticals and 3 mentions for Contineum Therapeutics. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Contineum Therapeutics' score of 0.55 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verrica Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Contineum Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market.

Contineum Therapeutics currently has a consensus target price of $20.00, indicating a potential upside of 55.52%. Verrica Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 189.61%. Given Verrica Pharmaceuticals' higher probable upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats Contineum Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Prothena?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Prothena had 4 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 11 mentions for Prothena and 7 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Prothena's score of -0.67 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prothena	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Verrica Pharmaceuticals has higher revenue and earnings than Prothena. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.83	-$17.89M	-$1.03	N/A
Prothena	$9.68M	51.86	-$244.09M	-$2.82	N/A

Verrica Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 189.61%. Prothena has a consensus price target of $21.78, suggesting a potential upside of 127.09%. Given Verrica Pharmaceuticals' higher possible upside, research analysts clearly believe Verrica Pharmaceuticals is more favorable than Prothena.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prothena	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

Verrica Pharmaceuticals has a net margin of -47.97% compared to Prothena's net margin of -260.92%. Prothena's return on equity of -43.44% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Prothena	-260.92%	-43.44%	-36.87%

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 10.4% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Verrica Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Prothena has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

Summary

Prothena beats Verrica Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Ocugen?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Ocugen's net margin of -1,192.18%. Verrica Pharmaceuticals' return on equity of -1,077.78% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Verrica Pharmaceuticals presently has a consensus target price of $17.00, suggesting a potential upside of 189.61%. Ocugen has a consensus target price of $9.75, suggesting a potential upside of 627.61%. Given Ocugen's stronger consensus rating and higher probable upside, analysts plainly believe Ocugen is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Ocugen had 13 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 20 mentions for Ocugen and 7 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Ocugen's score of 0.31 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Verrica Pharmaceuticals has higher revenue and earnings than Ocugen. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.83	-$17.89M	-$1.03	N/A
Ocugen	$4.41M	102.86	-$67.85M	-$0.24	N/A

Verrica Pharmaceuticals has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

Summary

Verrica Pharmaceuticals and Ocugen tied by winning 8 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 13.6% of Upstream Bio shares are held by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Upstream Bio had 7 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 14 mentions for Upstream Bio and 7 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Upstream Bio's score of -0.04 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Verrica Pharmaceuticals has higher revenue and earnings than Upstream Bio. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$3.32M	139.41	-$143.44M	-$2.91	N/A
Verrica Pharmaceuticals	$35.58M	2.83	-$17.89M	-$1.03	N/A

Verrica Pharmaceuticals has a net margin of -47.97% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Upstream Bio currently has a consensus price target of $38.75, suggesting a potential upside of 355.35%. Verrica Pharmaceuticals has a consensus price target of $17.00, suggesting a potential upside of 189.61%. Given Upstream Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Upstream Bio is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Upstream Bio has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

Summary

Verrica Pharmaceuticals beats Upstream Bio on 9 of the 16 factors compared between the two stocks.

How does Verrica Pharmaceuticals compare to Kamada?

Kamada (NASDAQ:KMDA) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kamada has a net margin of 11.21% compared to Verrica Pharmaceuticals' net margin of -47.97%. Kamada's return on equity of 7.73% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.21%	7.73%	5.41%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Kamada has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.50	$20.20M	$0.35	22.37
Verrica Pharmaceuticals	$35.58M	2.83	-$17.89M	-$1.03	N/A

Kamada has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

In the previous week, Kamada had 7 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 14 mentions for Kamada and 7 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 0.67 beat Kamada's score of -0.49 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kamada	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Verrica Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kamada presently has a consensus target price of $12.00, indicating a potential upside of 53.26%. Verrica Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 189.61%. Given Verrica Pharmaceuticals' higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Kamada beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Verrica Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRCA vs. The Competition

Export

Metric	Verrica Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$107.71M	$3.00B	$6.25B	$12.29B
Dividend Yield	N/A	1.98%	2.80%	5.31%
P/E Ratio	-5.70	17.22	20.63	25.23
Price / Sales	2.83	286.32	552.00	79.35
Price / Cash	N/A	56.35	27.48	37.30
Price / Book	3.79	3.93	9.67	6.63
Net Income	-$17.89M	$74.99M	$3.56B	$335.59M
7 Day Performance	-17.90%	-4.47%	-1.65%	-1.20%
1 Month Performance	-7.12%	-7.93%	-2.61%	-1.16%
1 Year Performance	-8.82%	29.34%	30.05%	28.10%

Verrica Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRCA Verrica Pharmaceuticals	2.0306 of 5 stars	$5.87 -6.4%	$17.00 +189.6%	-11.4%	$107.71M	$35.58M	N/A	40	Earnings Report
CTNM Contineum Therapeutics	3.0001 of 5 stars	$13.65 -6.1%	$19.50 +42.9%	+266.4%	$509.64M	N/A	N/A	31	Short Interest Decrease
PRTA Prothena	1.9088 of 5 stars	$9.66 -10.0%	$21.78 +125.4%	+33.6%	$505.70M	$9.68M	N/A	130
OCGN Ocugen	1.7402 of 5 stars	$1.48 -2.0%	$9.75 +558.8%	+76.7%	$501.01M	$4.47M	N/A	80	Analyst Upgrade
UPB Upstream Bio	1.7784 of 5 stars	$9.11 +0.2%	$39.00 +328.1%	-1.5%	$495.77M	$2.85M	N/A	38	News Coverage Positive News Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRCA) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. CTNM, PRTA, OCGN, UPB, and KMDA

How does Verrica Pharmaceuticals compare to Contineum Therapeutics?

Summary

How does Verrica Pharmaceuticals compare to Prothena?

Summary

How does Verrica Pharmaceuticals compare to Ocugen?

Summary

How does Verrica Pharmaceuticals compare to Upstream Bio?

Summary

How does Verrica Pharmaceuticals compare to Kamada?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Verrica Pharmaceuticals (VRCA) Competitors

VRCA vs. CTNM, PRTA, OCGN, UPB, and KMDA

How does Verrica Pharmaceuticals compare to Contineum Therapeutics?

Which has stronger earnings & valuation, CTNM or VRCA?

Is CTNM or VRCA more profitable?

Does the media refer more to CTNM or VRCA?

Which has more risk and volatility, CTNM or VRCA?

Do analysts recommend CTNM or VRCA?

Do institutionals and insiders believe in CTNM or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Prothena?

Does the media favor VRCA or PRTA?

Which has stronger valuation and earnings, VRCA or PRTA?

Do analysts rate VRCA or PRTA?

Is VRCA or PRTA more profitable?

Do insiders & institutionals believe in VRCA or PRTA?

Which has more risk and volatility, VRCA or PRTA?

Summary

How does Verrica Pharmaceuticals compare to Ocugen?

Is VRCA or OCGN more profitable?

Do institutionals and insiders believe in VRCA or OCGN?

Do analysts rate VRCA or OCGN?

Does the media favor VRCA or OCGN?

Which has better earnings & valuation, VRCA or OCGN?

Which has more risk & volatility, VRCA or OCGN?

Summary

How does Verrica Pharmaceuticals compare to Upstream Bio?

Do institutionals & insiders believe in UPB or VRCA?

Does the media favor UPB or VRCA?

Which has higher earnings and valuation, UPB or VRCA?

Is UPB or VRCA more profitable?

Do analysts rate UPB or VRCA?

Which has more volatility & risk, UPB or VRCA?

Summary

How does Verrica Pharmaceuticals compare to Kamada?

Do insiders & institutionals believe in KMDA or VRCA?

Is KMDA or VRCA more profitable?

Which has stronger valuation & earnings, KMDA or VRCA?

Which has more risk & volatility, KMDA or VRCA?

Does the media refer more to KMDA or VRCA?

Do analysts prefer KMDA or VRCA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA vs. The Competition

Verrica Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools